We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Stryker (SYK) to Your Portfolio
Read MoreHide Full Article
Stryker Corporation (SYK - Free Report) is poised for growth on solid second-quarter show, international growth and strong view.
Price Performance
Shares of this Zacks Rank #2 (Buy) stock have gained 28.5%, outperforming the industry’s growth of 3.2% on a year-to-date basis. Moreover, the stock has outpaced the S&P 500 Index’s rally of 0.8%.
Factors to Boost Stryker
Solid Q2 Results
Stryker delivered second-quarter 2019 adjusted earnings per share (EPS) of $1.98, beating the Zacks Consensus Estimate by 2.6%. The bottom line improved 12.5% year over year and exceeded the high end of the company’s guidance.
The Michigan-based medical device company reported revenues of $3.65 billion, which surpassed the Zacks Consensus Estimate by 1.4%. Revenues increased 9.9% on a year-over-year basis and 11.5% at constant currency.
Notably, the company gained on solid contributions from its three major segments — Orthopaedic, MedSurg and Neurotechnology & Spine.
In the second quarter, Stryker’s international organic sales grew 6.5%. Per management, robust gains in emerging markets, Europe and Australia were responsible for the rise in international organic sales.
Notably, the company sold 44 Mako robots globally in the quarter.
View Strong
Based on the second-quarter performance, Stryker now expects 2019 organic net sales growth in the range of 7.5-8%.
On a full-year basis, adjusted EPS is expected in the band of $8.15 to $8.25.
For the third quarter of 2019, adjusted EPS is anticipated within $1.87 and $1.92.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $14.87 billion, indicating an improvement of 9.3% from the year-ago period. For adjusted EPS, the same is pinned at $8.21, suggesting growth of 12.3% year-ago reported figure.
For the third quarter, the Zacks Consensus Estimate for revenues is pinned at $3.5 billion, calling for year-over-year growth of 10.5%. The same for adjusted EPS stands at $1.90, suggesting a rise of 12.4% year over year.
DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.
Intuitive Surgical’s long-term earnings growth rate is estimated at 13.3%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Here's Why You Should Add Stryker (SYK) to Your Portfolio
Stryker Corporation (SYK - Free Report) is poised for growth on solid second-quarter show, international growth and strong view.
Price Performance
Shares of this Zacks Rank #2 (Buy) stock have gained 28.5%, outperforming the industry’s growth of 3.2% on a year-to-date basis. Moreover, the stock has outpaced the S&P 500 Index’s rally of 0.8%.
Factors to Boost Stryker
Solid Q2 Results
Stryker delivered second-quarter 2019 adjusted earnings per share (EPS) of $1.98, beating the Zacks Consensus Estimate by 2.6%. The bottom line improved 12.5% year over year and exceeded the high end of the company’s guidance.
The Michigan-based medical device company reported revenues of $3.65 billion, which surpassed the Zacks Consensus Estimate by 1.4%. Revenues increased 9.9% on a year-over-year basis and 11.5% at constant currency.
Notably, the company gained on solid contributions from its three major segments — Orthopaedic, MedSurg and Neurotechnology & Spine.
Stryker Corporation Price and Consensus
Stryker Corporation price-consensus-chart | Stryker Corporation Quote
International Expansion
In the second quarter, Stryker’s international organic sales grew 6.5%. Per management, robust gains in emerging markets, Europe and Australia were responsible for the rise in international organic sales.
Notably, the company sold 44 Mako robots globally in the quarter.
View Strong
Based on the second-quarter performance, Stryker now expects 2019 organic net sales growth in the range of 7.5-8%.
On a full-year basis, adjusted EPS is expected in the band of $8.15 to $8.25.
For the third quarter of 2019, adjusted EPS is anticipated within $1.87 and $1.92.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $14.87 billion, indicating an improvement of 9.3% from the year-ago period. For adjusted EPS, the same is pinned at $8.21, suggesting growth of 12.3% year-ago reported figure.
For the third quarter, the Zacks Consensus Estimate for revenues is pinned at $3.5 billion, calling for year-over-year growth of 10.5%. The same for adjusted EPS stands at $1.90, suggesting a rise of 12.4% year over year.
Other Key Picks
Other top-ranked stocks in the broader medical space are DENTSPLY SIRONA (XRAY - Free Report) , Intuitive Surgical (ISRG - Free Report) and Baxter International (BAX - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.
Intuitive Surgical’s long-term earnings growth rate is estimated at 13.3%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>